186 related articles for article (PubMed ID: 35999268)
21. Hypermethylated and downregulated MEIS2 are involved in stemness properties and oxaliplatin-based chemotherapy resistance of colorectal cancer.
Wang X; Ghareeb WM; Zhang Y; Yu Q; Lu X; Huang Y; Huang S; Sun Y; Chi P
J Cell Physiol; 2019 Aug; 234(10):18180-18191. PubMed ID: 30859572
[TBL] [Abstract][Full Text] [Related]
22. CPT2 downregulation triggers stemness and oxaliplatin resistance in colorectal cancer via activating the ROS/Wnt/β-catenin-induced glycolytic metabolism.
Li H; Chen J; Liu J; Lai Y; Huang S; Zheng L; Fan N
Exp Cell Res; 2021 Dec; 409(1):112892. PubMed ID: 34688609
[TBL] [Abstract][Full Text] [Related]
23. Intense endoplasmic reticulum stress (ERS) / IRE1α enhanced Oxaliplatin efficacy by decreased ABCC10 in colorectal cancer cells.
Liu X; Wu B; Chen H; Sun H; Guo X; Sun T; Zhou D; Yang S
BMC Cancer; 2022 Dec; 22(1):1369. PubMed ID: 36585626
[TBL] [Abstract][Full Text] [Related]
24. MIR600HG suppresses metastasis and enhances oxaliplatin chemosensitivity by targeting ALDH1A3 in colorectal cancer.
Yao Y; Li N
Biosci Rep; 2020 Apr; 40(4):. PubMed ID: 32270866
[TBL] [Abstract][Full Text] [Related]
25. 53BP1 loss induces chemoresistance of colorectal cancer cells to 5-fluorouracil by inhibiting the ATM-CHK2-P53 pathway.
Yao J; Huang A; Zheng X; Liu T; Lin Z; Zhang S; Yang Q; Zhang T; Ma H
J Cancer Res Clin Oncol; 2017 Mar; 143(3):419-431. PubMed ID: 27838786
[TBL] [Abstract][Full Text] [Related]
26. A KLF4/PiHL/EZH2/HMGA2 regulatory axis and its function in promoting oxaliplatin-resistance of colorectal cancer.
Deng X; Kong F; Li S; Jiang H; Dong L; Xu X; Zhang X; Yuan H; Xu Y; Chu Y; Peng H; Guan M
Cell Death Dis; 2021 May; 12(5):485. PubMed ID: 33986248
[TBL] [Abstract][Full Text] [Related]
27. miR-122 Targets X-Linked Inhibitor of Apoptosis Protein to Sensitize Oxaliplatin-Resistant Colorectal Cancer Cells to Oxaliplatin-Mediated Cytotoxicity.
Hua Y; Zhu Y; Zhang J; Zhu Z; Ning Z; Chen H; Liu L; Chen Z; Meng Z
Cell Physiol Biochem; 2018; 51(5):2148-2159. PubMed ID: 30522111
[TBL] [Abstract][Full Text] [Related]
28. Development of a protein signature to enable clinical positioning of IAP inhibitors in colorectal cancer.
McCann C; Matveeva A; McAllister K; Van Schaeybroeck S; Sessler T; Fichtner M; Carberry S; Rehm M; Prehn JHM; Longley DB
FEBS J; 2021 Sep; 288(18):5374-5388. PubMed ID: 33660894
[TBL] [Abstract][Full Text] [Related]
29. Targeting hexokinase 2 increases the sensitivity of oxaliplatin by Twist1 in colorectal cancer.
Zhang B; Chan SH; Liu XQ; Shi YY; Dong ZX; Shao XR; Zheng LY; Mai ZY; Fang TL; Deng LZ; Zhou DS; Chen SN; Li M; Zhang XD
J Cell Mol Med; 2021 Sep; 25(18):8836-8849. PubMed ID: 34378321
[TBL] [Abstract][Full Text] [Related]
30. EVs delivery of miR-1915-3p improves the chemotherapeutic efficacy of oxaliplatin in colorectal cancer.
Xiao Z; Liu Y; Li Q; Liu Q; Liu Y; Luo Y; Wei S
Cancer Chemother Pharmacol; 2021 Dec; 88(6):1021-1031. PubMed ID: 34599680
[TBL] [Abstract][Full Text] [Related]
31. LncRNA CACS15 contributes to oxaliplatin resistance in colorectal cancer by positively regulating ABCC1 through sponging miR-145.
Gao R; Fang C; Xu J; Tan H; Li P; Ma L
Arch Biochem Biophys; 2019 Mar; 663():183-191. PubMed ID: 30639170
[TBL] [Abstract][Full Text] [Related]
32. Up-regulation of STRA6 predicts poor prognosis and contributes to oxaliplatin resistance in colorectal cancer.
Yang F; Xu P; Yao S; Li M; Bian Z; Huang Z
Pathol Res Pract; 2023 Mar; 243():154352. PubMed ID: 36758416
[TBL] [Abstract][Full Text] [Related]
33. miR-200b-3p mitigates oxaliplatin resistance via targeting TUBB3 in colorectal cancer.
Wu YZ; Lin HY; Zhang Y; Chen WF
J Gene Med; 2020 Jul; 22(7):e3178. PubMed ID: 32092782
[TBL] [Abstract][Full Text] [Related]
34. FadA promotes DNA damage and progression of Fusobacterium nucleatum-induced colorectal cancer through up-regulation of chk2.
Guo P; Tian Z; Kong X; Yang L; Shan X; Dong B; Ding X; Jing X; Jiang C; Jiang N; Yu Y
J Exp Clin Cancer Res; 2020 Sep; 39(1):202. PubMed ID: 32993749
[TBL] [Abstract][Full Text] [Related]
35. MiR-744 mediates the Oxaliplatin chemoresistance in colorectal cancer through inhibiting BIN1.
Zhou Y; He A; Zhang L; Yi G
Neoplasma; 2020 Mar; 67(2):296-303. PubMed ID: 31884801
[TBL] [Abstract][Full Text] [Related]
36. Knockdown of ADAM17 inhibits cell proliferation and increases oxaliplatin sensitivity in HCT-8 colorectal cancer through EGFR-PI3K-AKT activation.
Zhang Q; Wang C; Han X; Yang G; Ge Z; Zhang G
Biochem Biophys Res Commun; 2018 Sep; 503(4):2333-2339. PubMed ID: 29964008
[TBL] [Abstract][Full Text] [Related]
37. MiR-483-3p regulates oxaliplatin resistance by targeting FAM171B in human colorectal cancer cells.
Liang H; Xu Y; Zhang Q; Yang Y; Mou Y; Gao Y; Chen R; Chen C; Dai P
Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):725-736. PubMed ID: 30861353
[TBL] [Abstract][Full Text] [Related]
38. Protein Folding Stability Profiling of Colorectal Cancer Chemoresistance Identifies Functionally Relevant Biomarkers.
Quan B; Bailey MA; Mantyh J; Hsu DS; Fitzgerald MC
J Proteome Res; 2023 Jun; 22(6):1923-1935. PubMed ID: 37126456
[TBL] [Abstract][Full Text] [Related]
39. UPF1 promotes chemoresistance to oxaliplatin through regulation of TOP2A activity and maintenance of stemness in colorectal cancer.
Zhu C; Zhang L; Zhao S; Dai W; Xu Y; Zhang Y; Zheng H; Sheng W; Xu Y
Cell Death Dis; 2021 May; 12(6):519. PubMed ID: 34021129
[TBL] [Abstract][Full Text] [Related]
40. A role for ceramide glycosylation in resistance to oxaliplatin in colorectal cancer.
Madigan JP; Robey RW; Poprawski JE; Huang H; Clarke CJ; Gottesman MM; Cabot MC; Rosenberg DW
Exp Cell Res; 2020 Mar; 388(2):111860. PubMed ID: 31972222
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
